These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

695 related articles for article (PubMed ID: 27981708)

  • 1. Non-Viral CRISPR/Cas Gene Editing In Vitro and In Vivo Enabled by Synthetic Nanoparticle Co-Delivery of Cas9 mRNA and sgRNA.
    Miller JB; Zhang S; Kos P; Xiong H; Zhou K; Perelman SS; Zhu H; Siegwart DJ
    Angew Chem Int Ed Engl; 2017 Jan; 56(4):1059-1063. PubMed ID: 27981708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fast and Efficient CRISPR/Cas9 Genome Editing In Vivo Enabled by Bioreducible Lipid and Messenger RNA Nanoparticles.
    Liu J; Chang J; Jiang Y; Meng X; Sun T; Mao L; Xu Q; Wang M
    Adv Mater; 2019 Aug; 31(33):e1902575. PubMed ID: 31215123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing.
    Finn JD; Smith AR; Patel MC; Shaw L; Youniss MR; van Heteren J; Dirstine T; Ciullo C; Lescarbeau R; Seitzer J; Shah RR; Shah A; Ling D; Growe J; Pink M; Rohde E; Wood KM; Salomon WE; Harrington WF; Dombrowski C; Strapps WR; Chang Y; Morrissey DV
    Cell Rep; 2018 Feb; 22(9):2227-2235. PubMed ID: 29490262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-encapsulation of Cas9 mRNA and guide RNA in polyplex micelles enables genome editing in mouse brain.
    Abbasi S; Uchida S; Toh K; Tockary TA; Dirisala A; Hayashi K; Fukushima S; Kataoka K
    J Control Release; 2021 Apr; 332():260-268. PubMed ID: 33647431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing.
    Sago CD; Lokugamage MP; Paunovska K; Vanover DA; Monaco CM; Shah NN; Gamboa Castro M; Anderson SE; Rudoltz TG; Lando GN; Munnilal Tiwari P; Kirschman JL; Willett N; Jang YC; Santangelo PJ; Bryksin AV; Dahlman JE
    Proc Natl Acad Sci U S A; 2018 Oct; 115(42):E9944-E9952. PubMed ID: 30275336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of ionizable lipid nanoparticles and a lyophilized formulation for potent CRISPR-Cas9 delivery and genome editing.
    Sun Q; Zhang H; Ding F; Gao X; Zhu Z; Yang C
    Int J Pharm; 2024 Mar; 652():123845. PubMed ID: 38266942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing.
    Wilbie D; Walther J; Mastrobattista E
    Acc Chem Res; 2019 Jun; 52(6):1555-1564. PubMed ID: 31099553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal 2'-O-methyl phosphorothioate linkage modification pattern of synthetic guide RNAs for increased stability and efficient CRISPR-Cas9 gene editing avoiding cellular toxicity.
    Basila M; Kelley ML; Smith AVB
    PLoS One; 2017; 12(11):e0188593. PubMed ID: 29176845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis of lipid Nanoparticle-Mediated delivery of CRISPR-Cas9 RNP versus mRNA/sgRNA for gene editing in vitro and in vivo.
    Walther J; Porenta D; Wilbie D; Seinen C; Benne N; Yang Q; de Jong OG; Lei Z; Mastrobattista E
    Eur J Pharm Biopharm; 2024 Mar; 196():114207. PubMed ID: 38325664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing.
    Yin H; Song CQ; Suresh S; Wu Q; Walsh S; Rhym LH; Mintzer E; Bolukbasi MF; Zhu LJ; Kauffman K; Mou H; Oberholzer A; Ding J; Kwan SY; Bogorad RL; Zatsepin T; Koteliansky V; Wolfe SA; Xue W; Langer R; Anderson DG
    Nat Biotechnol; 2017 Dec; 35(12):1179-1187. PubMed ID: 29131148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High content analysis platform for optimization of lipid mediated CRISPR-Cas9 delivery strategies in human cells.
    Steyer B; Carlson-Stevermer J; Angenent-Mari N; Khalil A; Harkness T; Saha K
    Acta Biomater; 2016 Apr; 34():143-158. PubMed ID: 26747759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small extracellular vesicles (sEVs)-based gene delivery platform for cell-specific CRISPR/Cas9 genome editing.
    Dubey S; Chen Z; Jiang YJ; Talis A; Molotkov A; Ali A; Mintz A; Momen-Heravi F
    Theranostics; 2024; 14(7):2777-2793. PubMed ID: 38773978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. sgRNA Sequence Motifs Blocking Efficient CRISPR/Cas9-Mediated Gene Editing.
    Graf R; Li X; Chu VT; Rajewsky K
    Cell Rep; 2019 Jan; 26(5):1098-1103.e3. PubMed ID: 30699341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Advances of Cas9/sgRNA delivery system for gene editing].
    Hu X; Wang S; Yu L; Zhang X; Chen W
    Sheng Wu Gong Cheng Xue Bao; 2021 Nov; 37(11):3880-3889. PubMed ID: 34841792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postnatal Cardiac Gene Editing Using CRISPR/Cas9 With AAV9-Mediated Delivery of Short Guide RNAs Results in Mosaic Gene Disruption.
    Johansen AK; Molenaar B; Versteeg D; Leitoguinho AR; Demkes C; Spanjaard B; de Ruiter H; Akbari Moqadam F; Kooijman L; Zentilin L; Giacca M; van Rooij E
    Circ Res; 2017 Oct; 121(10):1168-1181. PubMed ID: 28851809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-viral and viral delivery systems for CRISPR-Cas9 technology in the biomedical field.
    He ZY; Men K; Qin Z; Yang Y; Xu T; Wei YQ
    Sci China Life Sci; 2017 May; 60(5):458-467. PubMed ID: 28527117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of Self-Destructing CRISPR/Cas Constructs for Targeted Gene Editing in the Retina.
    Li F; Hung SSC; Mohd Khalid MKN; Wang JH; Chrysostomou V; Wong VHY; Singh V; Wing K; Tu L; Bender JA; Pébay A; King AE; Cook AL; Wong RCB; Bui BV; Hewitt AW; Liu GS
    Hum Gene Ther; 2019 Nov; 30(11):1349-1360. PubMed ID: 31373227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells.
    Hendel A; Bak RO; Clark JT; Kennedy AB; Ryan DE; Roy S; Steinfeld I; Lunstad BD; Kaiser RJ; Wilkens AB; Bacchetta R; Tsalenko A; Dellinger D; Bruhn L; Porteus MH
    Nat Biotechnol; 2015 Sep; 33(9):985-989. PubMed ID: 26121415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of
    Qiu M; Glass Z; Chen J; Haas M; Jin X; Zhao X; Rui X; Ye Z; Li Y; Zhang F; Xu Q
    Proc Natl Acad Sci U S A; 2021 Mar; 118(10):. PubMed ID: 33649229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protocol for Delivery of CRISPR/dCas9 Systems for Epigenetic Editing into Solid Tumors Using Lipid Nanoparticles Encapsulating RNA.
    Woodward EA; Wang E; Wallis C; Sharma R; Tie AWJ; Murthy N; Blancafort P
    Methods Mol Biol; 2024; 2842():267-287. PubMed ID: 39012601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.